Limited Coverage Drugs - buprenorphine
|
Generic Name |
buprenorphine |
|---|---|
|
Strength |
100 mg/0.5 mL, 300 mg/1.5 mL |
|
Form |
extended-release subcutaneous injection |
| Special Authority Criteria | Approval Period |
|---|---|
|
For the management of moderate to severe opioid use disorder in adult patients: Patients must be induced and clinically stabilized on an equivalent of 8 mg to 24 mg of transmucosal buprenorphine-naloxone for a minimum of seven days. |
1 year |
Practitioner Exemptions
No practitioner exemptions.
Special Notes
- Patients are under the care of a health care provider with experience in the diagnosis and management of opioid use disorder.
- As stated in the Health Canada indication, buprenorphine extended-release injection should be used as part of a complete treatment plan that includes counselling and psychosocial support.
- As stated in the Health Canada indication, buprenorphine extended-release injection must be administered subcutaneously in the abdominal region by a healthcare provider.
